The MDM2 mutation occurred more frequently in the primary tumors vs. metastatic tumors (n = 27 (10.76%) vs. 2 (1.54%), p = 8.052 × 10−4, q = 0.106) The mutations that were enriched in the metastatic samples were RET (n = 9 (6.16%) vs. 5 (1.65%), p = 0.0170, q = 0.472) and TP53 (n = 91 (61.90%) vs. 156 (51.66%), p = 0.0420, q = 1). This evidence concerns the gene TP53 and metastatic neoplasm.